Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan.
Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan.
Biol Blood Marrow Transplant. 2019 Feb;25(2):e55-e59. doi: 10.1016/j.bbmt.2018.09.039. Epub 2018 Oct 4.
Umbilical cord blood transplantation (UCBT) is a possible option for patients with aplastic anemia (AA) without a related or unrelated HLA-matched donor, particularly if immunosuppressive therapy (IST) has failed or transplantation is urgently needed. However, a higher rate of graft failure after UCBT remains a major problem, and the optimal conditioning regimen for stable engraftment after UCBT has not been established. Here we investigated 6 adult patients with AA who underwent UCBT using a reduced-intensity conditioning (RIC) regimen comprising fludarabine 125 mg/m, cyclophosphamide 120 mg/kg, and 4 Gy of total body irradiation (Flu/CY/TBI4Gy) without antithymocyte globulin (ATG). Five patients underwent UCBT after IST failure, and 1 patient underwent UCBT as a first-line treatment due to a fulminant clinical finding of a neutrophil count of 0, despite granulocyte colony-stimulating factor administration. Regarding graft-versus-host disease (GVHD) prophylaxis, 2 patients received tacrolimus plus short-term methotrexate and 4 patients received tacrolimus plus mycophenolate mofetil, and all patients achieved sustained engraftment of both neutrophils and platelets, at a median of 17.5 days (range, 14 to 37 days) and 38.5 days (range, 31 to 86 days), respectively, with complete donor chimerism confirmed in all patients at a median of 14 days (range, 14 to 32 days). Three patients developed grade II acute GVHD (aGVHD), but grade III/IV aGVHD was not observed, whereas 4 patients developed chronic GVHD involving only skin. At the time of this report, all 6 patients were alive without the need for blood transfusion, at a median follow-up of 16 months (range, 12 to 131 months). Although further study is needed, our findings suggest that conditioning with Flu/CY/TBI4Gy without ATG might allow stable engraftment in UCBT for adults with AA.
脐带血移植(UCBT)是无相关或无关 HLA 匹配供体的再生障碍性贫血(AA)患者的一种可能选择,特别是在免疫抑制治疗(IST)失败或需要紧急移植的情况下。然而,UCBT 后移植物失败率较高仍然是一个主要问题,并且尚未确定 UCBT 后稳定植入的最佳条件方案。在这里,我们研究了 6 名接受包含氟达拉滨 125mg/m、环磷酰胺 120mg/kg 和全身照射 4Gy(Flu/CY/TBI4Gy)而无抗胸腺细胞球蛋白(ATG)的低强度条件方案的 AA 成人患者的 UCBT。5 名患者在 IST 失败后接受了 UCBT,1 名患者由于中性粒细胞计数为 0 的暴发性临床发现而作为一线治疗接受了 UCBT,尽管给予了粒细胞集落刺激因子。关于移植物抗宿主病(GVHD)预防,2 名患者接受他克莫司加短期甲氨蝶呤,4 名患者接受他克莫司加霉酚酸酯,所有患者均实现了中性粒细胞和血小板的持续植入,中位数分别为 17.5 天(范围 14 至 37 天)和 38.5 天(范围 31 至 86 天),所有患者在中位数为 14 天(范围 14 至 32 天)确认完全供体嵌合体。3 名患者发生 II 级急性 GVHD(aGVHD),但未观察到 III/IV 级 aGVHD,而 4 名患者发生仅累及皮肤的慢性 GVHD。在本报告时,6 名患者均存活且无需输血,中位随访时间为 16 个月(范围 12 至 131 个月)。尽管需要进一步研究,但我们的发现表明,无 ATG 的 Flu/CY/TBI4Gy 条件方案可能允许 AA 成人患者的 UCBT 实现稳定植入。